Loading organizations...
Phantom Neuro has raised $34.0M across 4 funding rounds.
Key people at Phantom Neuro.
Phantom Neuro has raised $34.0M in total across 4 funding rounds.
Phantom Neuro develops sophisticated neural-control systems, prominently featuring its minimally invasive peripheral neural interface, the Phantom X. This technology establishes a direct muscle-machine interface, facilitating intuitive control over advanced prosthetic limbs, robotics, and other complex electronic systems. The company's approach merges biological signals with precision engineering to enhance human capability.
The company was founded in 2020 by Dr. Connor Glass. His personal journey and a keen insight into bridging human biology with mechanical systems inspired the creation of Phantom Neuro. Dr. Glass's background includes research at The Johns Hopkins University School of Medicine, which contributed to the foundational understanding behind the company's core innovations.
Phantom Neuro’s products are designed for individuals with limb loss, motor impairments, and orthopedic injuries, enabling them to regain intuitive control and restored mobility. The company's overarching vision is to redefine human capability, empowering users with more natural and effective control over their interactions with advanced technology, thereby improving their functional independence.
Key people at Phantom Neuro.
Phantom Neuro has raised $34.0M in total across 4 funding rounds.
Phantom Neuro's investors include Oliver Jakobi, E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners.
Phantom Neuro is a neurotechnology company headquartered in Austin, Texas, developing Phantom X, a minimally invasive muscle-machine interface that captures muscle signals for intuitive control of robotic prosthetics, exoskeletons, and other devices[1][2][3][5]. It serves primarily amputees and individuals with limb differences or motor impairments, solving the problem of unnatural, cumbersome prosthetic control by enabling real-time, natural movement restoration—achieving up to 94% gesture accuracy and 85% hand/wrist functionality with minimal calibration[1][4][6]. The company offers clinical/preclinical testing services and targets expansion into elderly mobility aids and human augmentation, backed by a $19M Series A led by Ottobock in 2025, with strong growth via partnerships, a patient registry, and studies like ASCENT demonstrating superior performance over surface sensors[2][6][7].
Phantom Neuro emerged as a spinout from Johns Hopkins University School of Medicine, founded around 2022-2023 by Connor Glass, M.D., who serves as CEO with a background blending neuroscience, surgery, and a mission to restore control for those with disabilities[1][6][7]. Glass's idea stemmed from advances in neuroscience, AI, robotics, and minimally invasive surgery, aiming to create "natural extensions of the human body" beyond traditional prosthetics; in just three years, the company progressed from lab concepts to clinical studies like ASCENT and a $19M Series A in April 2025 led by Ottobock[2][6]. Pivotal early traction included funding from Blackrock Neurotech, Breakout Ventures, Draper Associates, LionBird Ventures, and Time BioVentures, plus an advisory board from CTRL-Labs, DARPA, Johns Hopkins, and Precision Neuro; the launch of a patient registry in late 2025 further accelerated community engagement[7].
Phantom Neuro rides the convergence of neurotechnology, AI-driven robotics, and human augmentation, addressing a massive market of ~2M US amputees and 50M elderly over 65 amid rising demand for intuitive assistive tech[2][3][8]. Timing is ideal post-2025 funding boom, fueled by MedTech investments (e.g., Ottobock's lead) and regulatory paths for outpatient implants, countering limitations of EMG surface tech or invasive neural interfaces[1][2][6]. It influences the ecosystem by partnering with prosthetics leaders, providing testing services, and opening registries to build clinician/amputee networks—paving for "sci-fi" prosthetics that surpass biological limbs, enhancing independence, mental health, and longevity[4][5][7].
Phantom Neuro is primed for market entry via accelerated clinical trials and Ottobock synergy, with Phantom X commercialization likely in 2026-2027, expanding from prosthetics to exoskeletons and augmentation[2][6]. Trends like AI precision medicine, aging populations, and robotics integration will propel growth, potentially evolving influence toward dominant human-machine interfaces that redefine mobility. This positions Phantom Neuro to turn physical limits into enhanced capabilities, fulfilling its mission where assistive devices truly extend the human body[3][4].
Phantom Neuro has raised $34.0M across 4 funding rounds. Most recently, it raised $19.0M Series A in April 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2025 | $19.0M Series A | Oliver Jakobi | E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners |
| Sep 12, 2022 | $6.0M Other Equity | ||
| Sep 1, 2022 | $6.0M Seed | E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners | |
| Mar 1, 2022 | $3.0M Seed | E1 Ventures, LionBird, Time BioVentures, Virginia Venture Partners |